Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effectiveness Study of Eximo's B-Laser™ Atherectomy Device for PAD Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02556255
Recruitment Status : Active, not recruiting
First Posted : September 22, 2015
Results First Posted : February 21, 2019
Last Update Posted : March 12, 2019
Sponsor:
Collaborator:
KCRI
Information provided by (Responsible Party):
Eximo Medical Ltd.

Brief Summary:
The aim of the study is to assess the safety and efficacy of the use of the Eximo's B-Laser™ catheter in subjects affected with Peripheral Artery Disease (PAD) in lower extremity arteries.

Condition or disease Intervention/treatment Phase
Peripheral Arterial Disease Device: B-Laser™ Atherectomy Catheter Not Applicable

Detailed Description:

This is a prospective, single-arm, multi-center, international, open-label, non-randomized clinical study.

All enrolled subjects will undergo atherectomy procedure, during which the B-Laser™ catheter will be used to perform atherectomy in target lesion, followed by any other adjunctive therapy (balloon and/or stent etc.). The procedure will be done according to standard hospital procedure for atherectomy. The steps of the operation before and after the operating of the B-Laser™ device are routinely used practice and will be done according to local practice at each hospital. For the post-atherectomy stage, as an adjunctive therapy in the procedure, any approved device may be used (balloon and/or stent etc.).

Subjects will then be followed for 12 months after the procedure.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness Evaluation of Eximo's B-Laser™ Atherectomy Device, in Subjects Affected With PAD
Actual Study Start Date : October 2015
Actual Primary Completion Date : August 2017
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: B-Laser™ Atherectomy Catheter
Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
Device: B-Laser™ Atherectomy Catheter
Laser atherectomy catheter based on 355 nm




Primary Outcome Measures :
  1. Number of Participants With 30 Day Freedom From Major Adverse Events [ Time Frame: 30 days post procedure ]
    1. Need for emergency surgical revascularization of the target limb
    2. Unplanned target limb amputation above the ankle
    3. Clinically driven Target Lesion Revascularization (TLR)
    4. Cardiovascular related deaths

  2. Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (1) [ Time Frame: Perioperative (until discharge), an average of 6 days ]

    (*NOTE: Device- or procedure-related AE refers only to the ATHERECTOMY PROCEDURE (with B-Laser™) and not the entire index procedure.)

    1. Clinically Significant Perforations requiring intervention
    2. Clinically Significant Dissections requiring intervention
    3. Clinically Significant Embolus requiring intervention
    4. Clinically Pseudo-aneurysm requiring intervention

  3. Number of Lesions With Technical Success Rate: the Ability of the B-Laser™ Catheter to Cross the Target Lesion Stenosis Over the Wire. [ Time Frame: Intraoperative (during the index procedure, after B-Laser™ catheter crossing, before adjunctive therapy) ]
    The technical success will be evaluated visually by the performing physician during procedure by fluoroscopy. It is evaluated per lesion and not per subject


Secondary Outcome Measures :
  1. Number of Participants With Perioperative (Until Discharge) Freedom From Device/Procedure* Related Adverse Events (2) [ Time Frame: Perioperative (until discharge), an average of 6 days ]

    (*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)

    1. Emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator
    2. Flow limiting dissection

  2. Number of Participants With 30 Day Freedom From Device/Procedure* Related Adverse Events [ Time Frame: 30 days post procedure ]

    (*NOTE: Device- or Procedure-related AE Refers Only to the ATHERECTOMY PROCEDURE (With B-Laser™) and Not the Entire Index Procedure.)

    1. Clinically Significant Dissections requiring intervention
    2. Clinically Significant Embolus requiring intervention
    3. Clinically Pseudo-aneurysm requiring intervention

  3. Number of Lesions With Post-intervention Residual Diameter Stenosis of <30% With Adjunctive Therapy Assessed by Fluoroscopic Angiography in Cases Where Adjunctive Therapy is Medically Applicable [ Time Frame: Intraoperative (at the end of the index procedure, after the last adjunctive therapy, e.g. last balloon or last stent) ]
    The ability of the B-Laser™ catheter to achieve a post-intervention residual diameter stenosis of <30% with adjunctive therapy assessed by fluoroscopic angiography in cases where adjunctive therapy is medically applicable

  4. Change in Ankle-Brachial Index (ABI) Post B-Laser™ Device Procedure Compared to Baseline [ Time Frame: baseline and 30 days, 6 months and 12 months post procedure ]

    Change in Ankle-Brachial Index (ABI) post B-Laser™ device procedure compared to baseline.

    ABI is calculated as the ratio of the ankle blood pressure to the arm blood pressure. The normal value ranges between 0.9 to 1.3.

    The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher ABI score at the later time point represents an improvement through time and vice versa.


  5. Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline [ Time Frame: baseline and 30 days, 6 months and 12 months post procedure ]

    Change in Rutherford Classification Post B-Laser™ Device Procedure Compared to Baseline.

    Rutherford Classification has seven stages, from Stage 0 to Stage 6, when the lower value indicate a better outcome: 0= Asymptomatic; 1= Mild claudication; 2= Moderate claudication; 3= Severe claudication; 4= Rest pain; 5= Ischemic ulceration not exceeding ulcer of the digits of the foot; 6= Severe ischemic ulcers or frank gangrene.

    The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent decrease while negative results represent increases, so lower Rutherford score at the later time point represents an improvement through time and vice versa.


  6. Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline [ Time Frame: baseline and 30 days, 6 months and 12 months post procedure ]

    Change in Grade of Walking Impairment Questionnaire (WIQ) Post B-Laser™ Device Procedure Compared to Baseline. WIQ score ranges from 0-100 with higher score indicating a better walking outcomes.

    The change is calculated as the value at the later time point minus the value at the earlier time point, when positive results represent increases while negative results represent decrease, so higher WIQ score at the later time point represents an improvement through time and vice versa.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is ≥ 18 years old.
  2. Subject is a candidate for endovascular intervention for peripheral artery disease in the lower extremities.
  3. Documented symptomatic atherosclerotic peripheral artery disease Rutherford Classification 2-4.
  4. Subject has infrainguinal target lesion(s) with any type of stenosis (naïve or recurrent) estimated to be ≥70% based on CT angiogram or other imaging modality.
  5. At least one patent tibial run-off vessel at baseline.
  6. Subject is capable and willing to comply with the scheduled follow up.
  7. Subject is able and willing to sign a written informed consent form (ICF).

Intraoperative inclusion criteria (by fluoroscopy angiogram):

  1. Reference vessel lumen diameter proximal to target lesion is ≥150% of the outer diameter of the B-Laser™ to be used.
  2. Target lesion has been crossed with a guidewire within the true lumen.
  3. Target lesion has a stenosis estimated to be ≥70%.

Exclusion Criteria:

  1. Target lesion is in a vessel graft or synthetic graft.
  2. Target lesion length >25 cm.
  3. Endovascular or surgical procedure performed less than or equal to 30 days prior to the index procedure OR Planned endovascular or surgical procedure 30 days after the index procedure.
  4. Intent to use other atherectomy device in the same procedure.
  5. Flow limiting dissection proximal to, distal to or in the target lesion.
  6. Evidence or history of intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months.
  7. Evidence or history of aneurysm in the target vessel within the past 2 months.
  8. History of bleeding diathesis, coagulopathy or inability to accept blood transfusions.
  9. History of heparin-induced thrombocytopenia (HIT).
  10. Significant acute or chronic kidney disease with a creatinine level >2.5 mg/dl, and/or requiring dialysis.
  11. Any thrombolytic therapy within 2 weeks of the index procedure.
  12. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days.
  13. Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
  14. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated.
  15. Serious illness that may affect subject compliance to protocol and at a minimum the 30-day follow-up.
  16. Participating in other clinical study that involves any kind of intervention, including pharmaceutical.
  17. Issue that in the judgment of the investigator, may affect the results of the study.
  18. Subject is pregnant or planning to become pregnant during the study period.

Intraoperative exclusion criteria (by fluoroscopy angiogram):

  1. Total occlusion of the Target lesion that cannot be crossed in the true lumen by 0.014" GW.
  2. Target lesion length >25 cm.
  3. Reference vessel lumen diameter proximal to target lesion is <150% of the outer diameter of the B-Laser™.
  4. Any clinical and/or angiographic complication attributed to the use of another device prior to the study procedure.
  5. Flow limiting dissection proximal, distal or in the target lesion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02556255


Locations
Layout table for location information
Poland
Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach
Katowice, Poland, 40635
Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
Poznan, Poland, 61848
Sponsors and Collaborators
Eximo Medical Ltd.
KCRI
Investigators
Layout table for investigator information
Study Director: Yossi Muncher, Ph.D., MBA Eximo Medical
Principal Investigator: Waclaw Kuczmik, Dr. Katowicach Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca
Principal Investigator: Grzegorz Oszkinis, Prof. Uniwersytetu Medycznego, Im. Karola Marcinkowskiego w Poznaniu
  Study Documents (Full-Text)

Documents provided by Eximo Medical Ltd.:

Layout table for additonal information
Responsible Party: Eximo Medical Ltd.
ClinicalTrials.gov Identifier: NCT02556255     History of Changes
Other Study ID Numbers: EX-PAD-01
First Posted: September 22, 2015    Key Record Dates
Results First Posted: February 21, 2019
Last Update Posted: March 12, 2019
Last Verified: February 2019

Keywords provided by Eximo Medical Ltd.:
Peripheral Arterial Disease
Peripheral Artery Disease
PAD
Atherosclerosis
Arterial Occlusive Diseases
Peripheral Vascular Diseases
PVD

Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Arterial Disease
Peripheral Vascular Diseases
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases